Provided by Tiger Fintech (Singapore) Pte. Ltd.

Valneva SE

5.98
-0.9913-14.22%
Post-market: 5.980.00000.00%16:10 EDT
Volume:41.37K
Turnover:246.15K
Market Cap:485.46M
PE:-34.35
High:6.27
Open:6.02
Low:5.74
Close:6.97
Loading ...

Pharming For 2025 Expects Product Sales Of €170M–180M And Total Revenues Of €180M–190M; Sees R&D Investments Of €90M–100M

Benzinga
·
20 Mar

Valneva FY Sales €169.60M Up From €153.7M YoY, Net Loss €12.2M Compared To Net Loss €101.4M YoY

Benzinga
·
20 Mar

Press Release: Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

Dow Jones
·
20 Mar

High Growth Tech Stocks In Europe For March 2025

Simply Wall St.
·
10 Mar

VALNEVA Declaration of shares and voting rights: February 28, 2025

GlobeNewswire
·
06 Mar

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

GlobeNewswire
·
03 Mar

Valneva reports positive CHMP opinion for adolescent label extension for Ixchiq

TIPRANKS
·
01 Mar

Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

GlobeNewswire
·
01 Mar

Valneva Price Target Maintained With a $17.00/Share by HC Wainwright & Co.

Dow Jones
·
01 Mar

Analysts Offer Insights on Healthcare Companies: Valneva (VALN) and Butterfly Network (BFLY)

TIPRANKS
·
28 Feb

Valneva Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
19 Feb

Valneva price target lowered to $17 from $18 at H.C. Wainwright

TIPRANKS
·
19 Feb

Valneva Expects Further Sales Growth

Dow Jones
·
18 Feb

Valneva 2025 Financial Outlook: Sales Revenue Projected At €170M-€180M, Total Revenue To Reach €180M-€190M; R&D Investments Of €90M-€100M

Benzinga
·
18 Feb

Valneva Preliminary 2024 Revenue €169.6M (+10% YoY), Product Sales Hit €163.3M (+13% YoY); Cash And Cash equivalents €168.3M

Benzinga
·
18 Feb

Press Release: Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

Dow Jones
·
18 Feb

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

GlobeNewswire
·
18 Feb

Shareholding declaration Valneva SE - January 2025

GlobeNewswire
·
07 Feb

Valneva jumps 19% after chikungunya vaccine wins UK approval

TIPRANKS
·
06 Feb

MHRA grants Valneva marketing authorization for chikungunya vaccine

TIPRANKS
·
06 Feb